On 3 July 2013, Forbes (Chinese edition) released its list of “2013 Forbes Best CEOs of China Listed Company” with 50 CEOs nominated, 6 of whom are chief executives of biomedicine enterprises. Mr. Li Bangliang, Chairman of the board of directors and General Manager of Huadong Medicine Co., Ltd (华东医药股份有限公司) (“Huadong Medicine”), being a member company of China Grand Enterprises Incorporation, was elected for the third time after being granted this award in 2009 and 2010, respectively.

Mr. Li Bangliang is the core leader of Huadong Medicine. He has been serving as the Chairman of the board of directors and General Manager of Huadong Medicine since 1993. Under his brilliant leadership, Huadong Medicine has grown from a small unknown factory at the edge of loss into a listed company with a market value of RMB17.9 billion. Mr. Li promoted the signing of a joint venture agreement between our Group and Merck & Co., Inc. of U.S.A., and led the development of our major products such as Corbrin Capsule (百令胶囊) and Cyspin (赛斯平). Today, Huadong Medicine has grown into a comprehensive medical enterprise with the integration of pharmaceutical manufacturing and distribution business. In 2012, the revenue of Huadong Medicine amounted to RMB14.579 billion and its net profit was RMB463 million. Moreover, the stock of Huadong Medicine is also popular among fund managers with substantial weighting in their portfolios. As at the end of the first quarter of 2013, Huadong Medicine ranked 46th among the most preferred stocks held by fund managers, and was held by an aggregate of 42 funds. In particular, the total number of shares held in funds’ portfolios amounted to 86,063,900 shares, representing 30.74% of the entire issued share capital of Huadong Medicine, and the total market value of funds’ investment was RMB3.68 billion.